Real-world Effectiveness and Safety of Treatment With Direct Antiviral Agents (DAAs) in Patients With Chronic Hepatitis C and Cirrhosis in Southern Area of China

Third Affiliated Hospital, Sun Yat-Sen University0 sites180 target enrollmentMarch 30, 2019

ConditionsChronic Hepatitis C

InterventionsDAAs

DrugsDAAs

Overview

Phase: Not Applicable
Intervention: DAAs
Conditions: Chronic Hepatitis C
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
Enrollment: 180
Primary Endpoint: SVR(Sustained Virologic Response)12
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

Detailed Description

This is a multi-center, open-label clinical study. This study was aimed to assess the real-world effectiveness and safety of treatment with listed DAAs in patients with CHC and cirrhosis in Southern area of China. The primary objectives of this study is as follows: To access the effectiveness and safety of 12-week/24-week treatment with listed DAAs in patients with CHC and cirrhosis in real-world clinical practice in Southern area of China. The proportion of participants with SVR12(Undetectable HCV RNA at 12 weeks after treatment completion RNA:Hepatitis C virus ribonucleic acid) was evaluated. This study aims to enroll 30 patients with CHC and cirrhosis in each treatment group. Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment. After 12-week/2-week treatment, all the patients will be followed up for 12 weeks.

Registry

clinicaltrials.gov

Start Date

March 30, 2019

End Date

September 30, 2019

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Responsible Party

Principal Investigator

Chaoshuang Lin

Professor/Chief physician

Third Affiliated Hospital, Sun Yat-Sen University

Eligibility Criteria

Inclusion Criteria

•Male and female subjects with age \>18 years old.
•HCV RNA ≥1×103IU/mL
•Genotype 1-6 HCV infection.
•Confirmed CHC defined as: (1)Confirmed HCV infection more than 6 months at baseline, including anti-HCV positive or HCV RNA positive for at least 6 months; (2)Confirmed HCV infection by liver biopsy one year before baseline.
•Negative pregnancy test for females of childbearing potential (18 years old to one year after menopause) at screening.
•Males and females of childbearing potential should agree to take mechanic contraceptives from screening to at least 6 months after discontinuation of treatment.
•Informed of, willing and able to comply with all of the protocol requirements and the investigational nature of the study.
•A signed written informed consent from patient.

Exclusion Criteria

•History of clinically significant medical condition associated with other chronic liver disease (including hemochromatosis, autoimmune hepatitis, Wilson's disease, α1-antitrypsin deficiency, alcoholic liver disease, drug-induced liver injury).
•Stomach disorder that could interfere with the absorption of the study drug.
•Serious or active medical or psychiatric illness. If the participant has received more than 12 months of treatment and the condition is stable, or the participant does not need any medicine during the previous 12 months, the participant is allowed to enrollment.
•Uncontrolled serious cardiovascular disease (such as ventricular tachyarrhythmia, myocardial infarction, angina or coronary disease); or uncontrolled hypertension (systolic pressure ≥160mmHg and/or diastolic pressure ≥100mmHg); or clinically relevant ECG abnormalities.
•Serious respiratory or renal diseases.
•Serious hematological diseases or increased risk of anemia (such as Mediterranean anemia, sickle cell disease, spherocytosis, gastrointestinal bleeding).
•Uncontrolled diabetes or other endocrinological diseases.
•Suspension of malignant tumor.
•Participant who has received organ or bone-marrow allograft, or plans to receive organ transplantation during the treatment.
•Any confirmed significant allergic reactions against any drug, or the therapeutic drug and its metabolites.

Arms & Interventions

Danoprevir Sodium triple therapy

DNV(Danoprevir Sodium)/PegIFNα(Peginterferon α-2a)/RBV(Ribavirin) : (1) DNV : 100mg (one tablet) orally twice daily for 12 weeks. (2) PegIFNα: 180ug subcutaneous infection on abdomen or thigh once a week for 12 weeks. (3) RBV: 500mg (5 tablets) orally twice daily for 12 weeks in patients weighing less than 75kg; 600mg (6 tablets) orally twice daily for 12 weeks in patients weighing ≥75kg. Dosing time: In the morning, participants will be instructed to take DNV and RBV with food or one hour after food. The drugs are not allowed to be cut or divided. The interval between DNV and RBV dosing time should be 12±2 hours.

Intervention: DAAs